Page 71 - ITPS-7-4

INNOSC Theranostics and
Pharmacological Sciences Role of saroglitazar in MASH

with an emphasis on sarcopenia and advanced cirrhosis, doi: 10.1002/hep.25762
is warranted to help validate saroglitazar as a primary drug 3. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev
for this liver disease. Gastroenterol Hepatol. 2013;10(11):686-690.

Acknowledgments doi: 10.1038/nrgastro.2013.171
None. 4. Targher G, Byrne CD. Clinical review: Nonalcoholic fatty
liver disease: A novel cardiometabolic risk factor for type 2
Funding diabetes and its complications. J Clin Endocrinol Metab.
2015;100(6):1887-1901.
None.
doi: 10.1210/jc.2012-3093
Conflict of interest 5. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev
Gastroenterol Hepatol. 2013;10(11):645-655.
The authors declare they have no competing interests.
doi: 10.1038/nrgastro.2013.182
Author contributions
6. Sanyal AJ, Friedman SL, McCullough A, Dimick-Santos L.
Conceptualization: Premashish Kar, Priyanshu Bhardwaj, Challenges and opportunities in drug and biomarker
Jata Shankar Kumar development for nonalcoholic steatohepatitis: Findings and
Formal analysis: Premashish Kar recommendations from an American Association for the
Investigation: Priyanshu Bhardwaj, Jata Shankar Kumar Study of Liver Diseases-U.S. Food and Drug Administration
Methodology: Priyanshu Bhardwaj, Jata Shankar Kumar, Joint Workshop. Hepatology. 2018;67(2):549-569.
Akul Chadha doi: 10.1002/hep.27678
Writing–original draft: Priyanshu Bhardwaj, Jata Shankar 7. Ratziu V, Harrison SA, Francque S, et al. Elafibranor,
Kumar an agonist of the peroxisome proliferator-activated
Writing–review & editing: Akul Chadha receptor-α and -δ, induces resolution of nonalcoholic
Ethics approval and consent to participate steatohepatitis without fibrosis worsening. Gastroenterology.
2016;150(5):1147-1159.e5.
The study was approved by the Institutional Ethics
Committee, Max Super Specialty Hospital in May 2022. 8. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone
treatment for patients with nonalcoholic steatohepatitis and
Written informed consent was taken from all the patient prediabetes or type 2 diabetes mellitus: A randomized trial.
before their participation. Ann Intern Med. 2016;165(5):305-315.

Consent for publication doi: 10.7326/M15-1774
All participants in the study gave their informed written 9. Kersten S, Stienstra R. The role and regulation of the
consent for their data to be published. peroxisome proliferator activated receptor alpha in human
liver. Biochimie. 2017;136:75-84.
Availability of data doi: 10.1016/j.biochi.2016.12.019
Data are available from the corresponding author upon 10. Belfort R, Harrison SA, Brown K, et al. A placebo-
reasonable request. controlled trial of pioglitazone in subjects with nonalcoholic
steatohepatitis. N Engl J Med. 2006;355(22):2297-2307.
References
doi: 10.1056/NEJMoa060326
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, 11. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone,
Wymer M. Global epidemiology of nonalcoholic fatty liver vitamin E, or placebo for nonalcoholic steatohepatitis.
disease-meta-analytic assessment of prevalence, incidence, N Engl J Med. 2010;362(18):1675-1685.
and outcomes. Hepatology. 2016;64(1):73-84.
doi: 10.1056/NEJMoa0907929
doi: 10.1002/hep.28431
12. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE, Holty JE.
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM,
Brunt EM, Cusi K, Sanyal AJ. The diagnosis and How much variance in biopsy‐proven nonalcoholic fatty
management of non-alcoholic fatty liver disease: Practice liver disease can be explained by established risk factors?
Hepatology. 2018;67(3):846-856.
guideline by the American Association for the Study of
Liver Diseases, American College of Gastroenterology, and 13. Kaur S, Kapoor R. Emerging strategies in the treatment
the American Gastroenterological Association. Hepatology. of non-alcoholic steatohepatitis. World J Gastrointest
2012;55(6):2005-2023. Pharmacol Therapeut. 2020;11(3):16-27.

Volume 7 Issue 4 (2024) 7 doi: 10.36922/itps.3560